Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Quetiapine Augmentation in Severe Obsessive Compulsive Disorder

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: November 15, 2005
Last updated: December 14, 2007
Last verified: December 2007

The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.

Condition Intervention Phase
Obsessive Compulsive Disorder
Drug: quetiapine fumarate
Drug: SSRI/Clomipramine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.

Secondary Outcome Measures:
  • Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.
  • Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.

Enrollment: 44
Study Start Date: April 2002
Study Completion Date: March 2006

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at least 12 weeks of treatment with SSRI or clomipramine

Exclusion Criteria:

  • Substance abuse or dependence, female patients who are pregnant, lactating or at risk of pregnancy, known intolerance or lack of response to quetiapine, use of antihypertensive medication with changing doses
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00254735

Research Site
Freiburg, Germany
Research Site
Lübeck, Germany
Sponsors and Collaborators
Study Director: AstraZeneca Germany Medical Director, MD AstraZeneca
  More Information

No publications provided Identifier: NCT00254735     History of Changes
Other Study ID Numbers: 5077/9059, D1441C09059
Study First Received: November 15, 2005
Last Updated: December 14, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AstraZeneca:
Obsessive Compulsive Disorder (OCD)

Additional relevant MeSH terms:
Compulsive Personality Disorder
Obsessive-Compulsive Disorder
Anxiety Disorders
Mental Disorders
Personality Disorders
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents processed this record on March 03, 2015